Published in:
Open Access
01-12-2009 | Research article
A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation
Authors:
Ha Vinh, Nguyen Thi Khanh Nhu, Tran Vu Thieu Nga, Pham Thanh Duy, James I Campbell, Nguyen Van Minh Hoang, Maciej F Boni, Phan Vu Tra My, Christopher Parry, Tran Thi Thu Nga, Pham Van Minh, Cao Thu Thuy, To Song Diep, Le Thi Phuong, Mai Thu Chinh, Ha Thi Loan, Nguyen Thi Hong Tham, Mai Ngoc Lanh, Bui Li Mong, Vo Thi Cuc Anh, Phan Van Be Bay, Nguyen Van Vinh Chau, Jeremy Farrar, Stephen Baker
Published in:
BMC Infectious Diseases
|
Issue 1/2009
Login to get access
Abstract
Background
Shigellosis remains considerable public health problem in some developing countries. The nature of Shigellae suggests that they are highly adaptable when placed under selective pressure in a human population. This is demonstrated by variation and fluctuations in serotypes and antimicrobial resistance profile of organisms circulating in differing setting in endemic locations. Antimicrobial resistance in the genus Shigella is a constant threat, with reports of organisms in Asia being resistant to multiple antimicrobials and new generation therapies.
Methods
Here we compare microbiological, clinical and epidemiological data from patients with shigellosis over three different periods in southern Vietnam spanning14 years.
Results
Our data demonstrates a shift in dominant infecting species (S. flexneri to S. sonnei) and resistance profile of the organisms circulating in southern Vietnam. We find that there was no significant variation in the syndromes associated with either S. sonnei or S. flexneri, yet the clinical features of the disease are more severe in later observations.
Conclusions
Our findings show a change in clinical presentation of shigellosis in this setting, as the disease may be now more pronounced, this is concurrent with a change in antimicrobial resistance profile. These data highlight the socio-economic development of southern Vietnam and should guide future vaccine development and deployment strategies.
Trial Registration
Current Controlled Trials ISRCTN55945881